Physician profile
Mehandar Kumar
NPI 1790082550
$4,191.11
in general payments reported to CMS, 2019-2025
36 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $72.41 · 2021: $67.04 · 2022: $416 · 2023: $995 · 2024: $978 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.03 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $732.98 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Abbvie INC. | $700.66 | 2019-2025 | |
| Janssen Biotech, INC. | $572.92 | 2022-2025 | Erleada, Darzalex, Balversa |
| Astrazeneca Pharmaceuticals LP | $373.09 | 2019-2025 | Farxiga, Tagrisso, Breztri |
| Amgen INC. | $318.87 | 2019-2024 | Lumakras, Blincyto |
| Janssen Scientific Affairs, LLC | $242.09 | 2022-2024 | Balversa, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $158.65 | 2019-2025 | |
| Genzyme Corporation | $146.38 | 2023-2025 | |
| Glaxosmithkline, LLC. | $119.34 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Eisai INC. | $106.79 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $67.10 | 2022-2025 | Monoferric |
| Novo Nordisk INC | $55.13 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.83 | 2019 | |
| Merck Sharp & Dohme LLC | $41.72 | 2019-2024 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $39.71 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38.45 | 2019 | |
| Exact Sciences Corporation | $37.88 | 2023 | Cologuard Collection Kit |
| Incyte Corporation | $36.13 | 2022-2025 | Jakafi |
| Daiichi Sankyo INC. | $33.42 | 2024-2025 | Datroway, Vanflyta |
| Taiho Oncology, INC. | $31.42 | 2025 | |
| Celgene Corporation | $27.61 | 2022-2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $22.67 | 2025 | |
| Stemline Therapeutics INC. | $22.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.52 | 2024 | Ultomiris |
| Genentech USA, INC. | $21.33 | 2025 | Venclexta |
| Genmab U.S., INC. | $20.36 | 2023 | Tivdak |
| Tersera Therapeutics LLC | $19.00 | 2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $18.18 | 2025 | Libtayo |
| Gilead Sciences, INC. | $16.88 | 2023 | Trodelvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.62 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Cti Biopharma Corp. | $14.88 | 2023 | Vonjo |
| Seagen INC. | $13.51 | 2022 | |
| Lilly USA, LLC | $11.58 | 2019 | |
| Sanofi Pasteur INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehandar Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.